UroGen Q1 2026: ZUSDURI revenue $29.2M (+109% QoQ); net loss narrows to $0.47/share

UroGen Pharma Ltd.

Total revenue $51.0M, up 152% YoY on ZUSDURI launch and JELMYTO growth.
ZUSDURI net revenue $29.2M, 109% sequential growth; 256 unique prescribers as of March 31.
JELMYTO revenue $21.7M (+7% YoY); FY 2026 guidance reaffirmed at $97–101M.
Net loss $23.6M ($0.47/share) vs $43.8M ($0.92/share) in Q1 2025; cash $140.3M.
UGN-103 NDA submission on track for H2 2026; six-month durability data expected mid-2026.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

UroGen Pharma Ltd. reported the first quarter ended March 31, 2026 results: revenue ZUSDURI™ generated revenue of $29.2 million in Q1 2026.

Period: the first quarter ended March 31, 2026
Revenue: ZUSDURI™ generated revenue of $29.2 million in Q1 2026
Result: reported results

Exact text from the filing

On May 6, 2026, UroGen Pharma Ltd. (the “Company”) announced its financial results for the quarter ended March 31, 2026.

View on SEC.gov

Browse all earnings releases →

UroGen Pharma Ltd. filing history →

Source: SEC EDGAR

accession 0001437749-26-015018

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.